◆ 会议时间：2025年3月26-29日
◆ 会议地点：法国 巴黎

◆ 会议简介：

2025年欧洲肺癌大会(ELCC2025)将于2025年3月26-29日在法国巴黎举行，会议由欧洲肿瘤内科学会（ESMO）与国际肺癌研究协会（IASLC）联合组织。ELCC由代表胸部肿瘤专家的最重要的多学科学会联合协作举办，它们共同致力于促进科学发展、传播教育和提高全世界肺癌专家的实践。领域国际医学会议网；会议将回顾当前肺癌治疗的最新技术，更新您在预防、筛查、检测等方面的知识，与会者将从其全面而令人振奋的科学计划宣中受益。自2008年首次举办以来，ELCC已成为该领域专业人士的首要会议，大会与会者包括肿瘤内科医师、放射肿瘤学家、胸外科医生、呼吸内科医师/肺科医师、介入放射科医师、病理学家等众多专家学者。本次欧洲肺癌大会(ELCC)预计有超过2000名专业人士与会。

国际肺癌研究协会（IASLC）成立于1974年，是全球唯一致力于肺癌研究的组织，由致力于肺癌领域研究的专家们发起和创立,成员包括来自于全球100多个国家的5000多名肺癌专家。IASLC在肺癌和其他胸部恶性肿瘤的病因学、流行病学、预防、诊断、治疗以及与之相关的领域开展深入研究，为医学团体与大众服务。

欧洲肿瘤内科学会（ESMO）成立于1975年，是欧洲领先的肿瘤内科学专业组织，现在全球150多个国家和地区拥有超过17,000名会员，是肿瘤学教育和信息的参考学会，ESMO致力于支持其会员在快速发展的专业环境中得到发展与进步。作为一个非营利组织，ESMO一直以推动癌症护理和治疗为使命，致力于推进肿瘤医学专业的发展，以多学科的方法来促进癌症的治疗和护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

European Lung Cancer Congress (ELCC 2025)

Date:
26-29 March 2025

Venue:
Paris, France

We invite you to save the date for the European Lung Cancer Congress (ELCC 2025), taking place in Paris, France, from 26-29 March 2025. 

The European Lung Cancer Congress is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide. 

Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme. 

Make sure you connect to this highly interactive meeting and share your expertise with lung cancer specialists from all over the world.

摘要征文投稿：

Abstract submission deadlines 

点此提交摘要>>>Submit Abstract>>>

• ELCC 2025 Abstract Regulations

Outcome notifications

Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by early February.

Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by end February.

Submission categories

• Tumour biology and pathology
• Translational research
• Prevention, early detection, epidemiology, tobacco control
• Imaging and staging
• SCLC
• Early stage NSCLC
• Locally advanced NSCLC
• Advanced NSCLC
• Metastases to and from the lung
• Mesothelioma
• General interest

Late-breaking abstracts (LBA) 

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.  

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 14 January 2025 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ELCC 2025.

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline of Tuesday, 14 January 2025.   

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by Tuesday, 18 February 2025. 

Trial in progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ELCC 2025.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

1. Background
2. Trial design

Notes:

• Recruitment must have already begun or have been completed by the abstract submission deadline of 14 January 2025.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation or Mini Oral.
• Encore TiP abstracts will NOT be accepted.

Publication schedule for accepted abstracts

Details regarding the publication of accepted abstracts will be available on will be released online according to a schedule which will be available on the ELCC website in due course.   

Details regarding ESMO PR activities will be made available 10 days prior to the Congress.

Embargo policy

Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above.

Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official programme session during which the study is presented.

Presentation and publication of accepted abstracts 

The ELCC 2025 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Proffered Paper: Oral presentation of original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral: Short oral presentation of good quality data, followed by expert discussion and perspectives.
• Poster: Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

All accepted abstracts will be published in the ELCC 2025 Abstract Book, a supplement of the official IASLC journal, Journal of Thoracic Oncology.

ELCC 2025 注册费：

Registration includes:

• Participation in scientific and educational live sessions with the possibility to interact with the expert panel
• Onsite networking opportunities with faculty and peers
• Entry to the Poster and e-Poster area
• Interaction with the industry partners in the trade exhibition
• Participation in the Industry Satellite Symposia
• Access to the Virtual Platform to view live-streamed sessions and to view the missed sessions on-demand
• Post-congress resources
• Coffee breaks

Registration fees and deadlines

Individual registration will remain open for the duration of the congress. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines.

ESMO Membership must be active seven (7) days prior to the registration deadline for the reduced member registration fee to be applied. Please visit the membership page to check eligibility criteria, benefits, and to complete the membership application. 

* Applicable to ESMO/IASLC/ESTS/ESTRO Members from developing countries only. At the time of application, developing countries are defined by ESMO according to the World Bank classification of low, lower-middle and upper-middle countries based on the Gross National Income (GNI) per capita. Download the PDF outlining which countries are eligible for the discounted registration fees.

** ESMO/IASLC/ESTS/ESTRO Members must be under 40 and in training to qualify for this fee

Please send an email to registration@esmo.org to request one of the badge in the table above "Other registration fees".

Webcasts

The official sessions and Industry Satellite Symposia will be available on-demand on the Congress Virtual Platform until Monday 31 March 2025 at 12:00 CET, for all registered participants.
Once the Congress Virtual Platform is closed, the on-demand content will be transferred to OncologyPRO.

◆ 参会对象：肿瘤科医师、放射（肿瘤）科医师，胸外科医师，呼吸内科医师，介入放射科医师，病理科医师，护士以及从事肿瘤护理与研究的其他相关专业人士等。